drugset
drugset / Trial / NCT03530917

A Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants.

NCT03530917 ↗

Phase 1 Completed 70 enrolled Hoffmann-La Roche
RandomizedSequentialDouble-blindTreatment

Summary

To evaluate the safety and tolerability of single and multiple ascending doses of oral RO7020531 in Chinese healthy participants.

Timeline

Start
2018-05-15
Primary completion
2019-05-15
Completion
2019-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject RUZOTOLIMOD Small molecule 40 mg Oral
Subject RUZOTOLIMOD Small molecule 100 mg Oral
Subject RUZOTOLIMOD Small molecule 140 mg Oral
Subject RUZOTOLIMOD Small molecule 150 mg Oral
Subject RUZOTOLIMOD Small molecule 170 mg Oral

Indications

No indication recorded.